Institutional investors increase investment in Gilead Sciences, boosting market confidence.

Gilead Sciences, Inc. has seen increased investment from various institutional investors, signaling confidence in the biopharmaceutical firm. The stock opened at $83.05, with a market cap of $103.47 billion. For the last quarter, Gilead reported earnings per share of $2.01, exceeding expectations, and announced a quarterly dividend of $0.77. Analysts have upgraded their ratings, with price targets reaching up to $93.00.

September 18, 2024
7 Articles

Further Reading